Vectura Group PLC (LON:VEC) had its price objective raised by equities research analysts at Numis Securities Ltd from GBX 246 ($3.21) to GBX 252 ($3.29) in a report released on Monday. The brokerage presently has a “buy” rating on the stock. Numis Securities Ltd’s price target would suggest a potential upside of 75.37% from the company’s current price.

A number of other analysts have also issued reports on VEC. Stifel Nicolaus reissued a “buy” rating and issued a GBX 250 ($3.26) price target on shares of Vectura Group PLC in a research note on Thursday, May 26th. Peel Hunt reissued a “buy” rating and issued a GBX 200 ($2.61) price target on shares of Vectura Group PLC in a research note on Thursday, June 30th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 230 ($3.00) price target on shares of Vectura Group PLC in a research note on Wednesday, July 6th. Citigroup Inc. reissued a “buy” rating and issued a GBX 215 ($2.81) price target on shares of Vectura Group PLC in a research note on Thursday, July 28th. Finally, FinnCap reissued a “buy” rating and issued a GBX 225 ($2.94) price target on shares of Vectura Group PLC in a research note on Tuesday, August 30th. Eight investment analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of GBX 222.25 ($2.90).

Vectura Group PLC (LON:VEC) opened at 143.70 on Monday. The firm’s market capitalization is GBX 590.06 million. The stock’s 50 day moving average price is GBX 140.33 and its 200-day moving average price is GBX 156.42. Vectura Group PLC has a 12 month low of GBX 122.90 and a 12 month high of GBX 200.10.

In related news, insider Derodra,Andrew sold 263,364 shares of the firm’s stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of GBX 152 ($1.98), for a total transaction of £400,313.28 ($522,533.98).

About Vectura Group PLC

Vectura Group plc is a product development company. The Company focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases (airways diseases). The Company has eight products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to pharmaceutical companies.

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.